Cogstate lands five Phase 3 trials as FY27 backlog strengthens

Five Phase 3 Trials Drive Cogstate’s First-Quarter Wins

Cogstate Ltd (ASX:CGS) opened FY27 with US$25.1 million in net sales contracts, as the clinical-trial technology provider won five Phase 3 studies in bipolar disorder or depression across two customers. Those programs contributed more than 80% of the quarter’s contract value, giving the result a clear concentration in mood-disorder work rather than a broad-based breakdown across a large number of smaller awards.

The quarterly total was up from US$21.4 million in the prior corresponding period and followed a record US$89.0 million in contracts for FY26. The latest result extends the momentum described in Cogstate’s record FY26 contract performance, but the company has not provided earnings guidance with this update.

Contracted Revenue Reaches US$143.7 Million

Cogstate’s contracted revenue position increased 41% year on year to US$143.7 million at 30 September, including revenue recognised during the quarter. The contracted pool covers US$56.8 million for FY27 and US$86.9 million across FY28 to FY33. FY27 contracted revenue rose from US$48.3 million at the end of June, while the amount contracted for FY28 increased from US$31.4 million to US$39.7 million.

The figures improve forward visibility, but they are not the same as reported revenue. Clinical-trial contracts are recognised over their lives as milestones are achieved, with Phase 3 studies potentially running for four to five years. Trial enrolment, customer timing and delivery milestones will therefore determine when the backlog reaches the income statement.

Longer Trials Temper Near-Term Revenue Conversion

Of the US$25.1 million in new contracts signed during 1Q27, US$8.4 million contributed to contracted FY27 revenue, an in-year yield of 34%. Cogstate said that was below its typical first-quarter level because licence fees represented only 7% of sales, compared with a historical range of 20% to 25%, while the quarter included a significant proportion of longer-duration Phase 3 studies.

That trade-off shifts some of the benefit of the wins further into the future. The stronger FY28 coverage is a useful counterweight to the softer near-term conversion, but the filing leaves open how quickly the five mood-disorder programs will enrol and generate milestone-based revenue. The 2026 annual general meeting is scheduled for 15 October, while the next operating updates should provide a clearer test of backlog conversion.